2021
DOI: 10.2478/pielxxiw-2021-0009
|View full text |Cite
|
Sign up to set email alerts
|

COVID-19 vaccine – technical aspects of vaccination

Abstract: Introduction. All over the world the fight against the SARS-CoV-2 virus, which causes COVID-19, has already begun. Very quick development and testing of medicinal preparations with such a high efficiency (94-95%), which can be administered to adult patients for mass immunization, makes this fight possible. The production and delivery of a huge number of vaccines remains a challenge, but an undoubtedly important aspect is the safe and compliant administration of medicinal preparations. People currently authoriz… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
2
2

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 3 publications
0
3
0
Order By: Relevance
“…Now, one of the main weapons that has proved able to fight the virus [ 6 ] in an effective way is the vaccine against SARS-CoV-2 [ 6 ]. Nevertheless, the vaccination rate is not satisfactory in some countries [ 7 , 8 ], due to people’s refusal to receive one of the approved vaccines or booster doses [ 9 ].…”
Section: Introductionmentioning
confidence: 99%
“…Now, one of the main weapons that has proved able to fight the virus [ 6 ] in an effective way is the vaccine against SARS-CoV-2 [ 6 ]. Nevertheless, the vaccination rate is not satisfactory in some countries [ 7 , 8 ], due to people’s refusal to receive one of the approved vaccines or booster doses [ 9 ].…”
Section: Introductionmentioning
confidence: 99%
“…The bases of these vaccines are diverse and some of the approved ones are based on new technology platforms (Yoo 2021), speci cally, they are nucleotide-based. Nucleotide-based vaccines (NBVs) offer a relatively quick production cycle (Jaciubek and Prasek 2021) Their main strategy is to exploit the molecular machinery responsible for protein synthesis in the cells to produce a viral protein, which is presented on the cell surface and, in turn, stimulates an effective immune response (Kowalczyk et al 2016) (Ho et al 2021).…”
Section: Introductionmentioning
confidence: 99%
“…Nucleotide-based vaccines (NBVs) offer a relatively quick production cycle [15] Their main strategy is to exploit the molecular machinery responsible for protein synthesis in the cells to produce a viral protein, which is presented on the cell surface and, in turn, stimulates an effective immune response [16] [17].…”
Section: Introductionmentioning
confidence: 99%